tremfya market growth, tremfya market demand, tremfya market insights, tremfya market trends, tremfya market research, tremfya market forecast
How much is the tremfya market worth, and how is it expected to expand?
The tremfya market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to the rising prevalence of psoriasis and psoriatic arthritis, increasing focus on targeted therapies, rising healthcare investments, a growing number of specialty clinics, and increased adoption of biologics in dermatology and rheumatology.
The tremfya market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing healthcare infrastructure, rising adoption of point-of-care testing, increasing investment in healthcare research, and growing focus on precision medicine. Major trends in the forecast period include advancements in treatment modalities, personalized medicine approaches, technological integration in patient monitoring, integration of artificial intelligence (AI), and advancements in injection devices.
Get Your Free Sample of The Global Tremfya Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20343&type=smp
Which industry factors have accelerated the tremfya market’s expansion?
The increasing prevalence of autoimmune diseases is expected to propel the growth of the tremfya market going forward. Autoimmune diseases refer to conditions in which the body’s immune system mistakenly attacks its cells, tissues, or organs, perceiving them as foreign invaders. The increasing prevalence of autoimmune diseases is due to genetic predisposition, environmental triggers, lifestyle changes, increased awareness, and improved diagnostic capabilities. Tremfya is a monoclonal antibody targeting interleukin-23 (IL-23) that helps manage autoimmune diseases by modulating the immune system’s overactive response, reducing inflammation, and alleviating symptoms in conditions such as psoriasis and psoriatic arthritis. For instance, in June 2024, according to a report published by the Australian Institute of Health and Welfare, an Australian-based governmental organization, in 2022, there were 10,000 hospitalizations for rheumatoid arthritis, marking a 25% increase from 8,000 in the previous year, with a hospitalization rate of 39 per 100,000 people. Therefore, the increasing prevalence of autoimmune diseases is driving the growth of the tremfya market.
What are the primary segments of the tremfya market?
The tremfya market covered in this report is segmented –
1) By Indication: Moderate-To-Severe Plaque Psoriasis; Active PsA
2) By Formulation: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies
4) By End User: Adult Patients; Geriatric Patients
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/tremfya-global-market-report
Which firms are leading the tremfya market?
Major companies operating in the tremfya market are Johnson & Johnson
Which market trends are set to define the future of the tremfya market?
The key trend in the tremfya market is gaining regulatory approvals to expand its treatment indications, such as for moderate-to-severe Crohn’s disease, which broadens its patient base and market potential. Regulatory approvals refer to the official authorization granted by authorities such as the Food and Drug Administration (FDA) or European Medicines Agency (EMA), allowing a drug to be marketed for specific uses after demonstrating its safety, efficacy, and quality. For instance, in September 2024, Johnson & Johnson, a US-based pharmaceutical industry company, received FDA approval for TREMFYA (guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis, marking it as the first dual-acting interleukin-23 inhibitor approved for this condition. The decision is based on positive results from the Phase 2b/3 QUASAR study, which showed that approximately 50% of patients achieved clinical remission after 44 weeks of treatment. TREMFYA targets interleukin-23, helping to normalize the inflammatory response in the colon.
Which geographic trends are shaping the tremfya market, and which region has the highest market share?
North America was the largest region in the tremfy market in 2024. The regions covered in the tremfya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Tremfya Market Report 2025 Offer?
The tremfya market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Tremfya (guselkumab) is a biologic medication used to treat moderate to severe plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by inhibiting interleukin-23 (IL-23), a protein involved in the inflammatory processes of these conditions. Tremfya is administered via subcutaneous injection once every 8 weeks after initial loading doses.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20343
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
